StockData
Valneva SE logo

Valneva SE (VALN) company profile

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.57−0.08 (-1.50%)

Close on Nov 17, 2026Market cap $482.87MP/E –Yield –

About Valneva

Biological Products, (No Diagnostic Substances), SIC 2836

Valneva SE is a specialty vaccine company that discovers, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with significant unmet medical needs. The company's commercialized product portfolio features travel vaccines, including IXIARO for the prevention of Japanese encephalitis, DUKORAL for cholera and traveler's diarrhea caused by LT-ETEC, and IXCHIQ for chikungunya. Valneva serves travelers, military personnel, and global populations vulnerable to endemic infectious threats. Additionally, it advances late-stage clinical candidates, such as a Lyme disease vaccine developed in partnership with Pfizer and a tetravalent Shigella vaccine candidate.

The company operates manufacturing and research facilities across Europe, including production sites in Scotland and Sweden. It conducts business and maintains wholly owned operating subsidiaries in France, Austria, Scotland, Sweden, England and Wales, Canada, and the United States. Valneva maintains its registered corporate headquarters in Lyon, France.

Summary of the business section of Valneva's latest annual report, written by StockData.

Company profile

Company

Legal name
Valneva SE
Founded
1999
Headquarters
Saint-Herblain, I0
Address
6, Rue Alain Bombard 44800
Phone
33 2 28 07 37 10
Employees
140, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
I0
Fiscal year ends
December 31
Auditor
Deloitte & Associes, Paris, France

Stock & identifiers

Ticker
VALN
Exchange
Nasdaq
IPO date
May 7, 2021
Shares outstanding
174M, Dec 31, 2025
Filer category
Accelerated filer
SEC CIK
1836564
CUSIP
92025Y103
ISIN
US92025Y1038
FIGI
BBG00ZZPBH08
Share class FIGI
BBG00ZZPBHX2
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Valneva's leadership is listed in its proxy statement (Form DEF 14A).

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 7, 2021
Offer price
$26.41
Exchange
Nasdaq
First trading day
May 5, 2021
First-day close
$26.41-0.0%
Lock-up ends (est.)
Nov 1, 2021

“Our ADSs have been approved for listing on the Nasdaq Global Select Market under the symbol “VALN.” Our ordinary shares are listed on Euronext Paris under the symbol “VLA.” The initial public offering price is $26.411 per ADS in the U.S.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“The site supports multi‑product manufacturing and serves as our viral vaccine center of excellence, employing approximately 140 staff.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?